# US 2024/0189388 A1 · Medication for treating lung injury

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189388 A1
- Document ID: US20240189388A1
- Status: Published application
- Kind: A1
- Application number: 18/556,310
- Filed: 2021-11-19
- Published: 2024-06-13
- Earliest claimed: 2021-04-25
- Assignees: Shanghai Seme Cell Technology Co., Ltd
- Applicants: Shanghai Seme Cell Technology Co., Ltd.
- Inventors: Xifan HOU; Wenjie ZHANG; Bin WANG
- Web page: https://patentgrep.com/patent/US20240189388A1

## CPC

- A61K 38/1709: {from mammals}
- A23K 20/147: Polymeric derivatives, e.g. peptides or proteins
- A23L 33/17: Amino acids, peptides or proteins
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23K: FODDER
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The present disclosure relates to a medication for treating a lung injury. Specifically, the present disclosure provides a use of an annexin in preparation of a composition or a formulation. The composition or formulation has one or more uses selected from the following group consisting of: (i) preventing and/or treating a lung injury; and (ii) reducing neutrophil aggregation.

## Claims

### Claim 1

(canceled)

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

A method for (i) preventing and/or treating a lung injury and/or (ii) reducing a quantity of neutrophils, comprising:
administering annexin at a dose of 0.2-5 mg/kg to a subject, wherein the subject is a human or a non-human mammal.

### Claim 22 (depends on 21)

The method of claim 21, wherein the annexin comprises annexin A5.

### Claim 23 (depends on 21)

The method of claim 21, wherein the lung injury is selected from a group consisting of: an acute lung injury, a respiratory distress syndrome, and a combination thereof.

### Claim 24 (depends on 21)

The method of claim 21, wherein the lung injury is caused by an increase of neutrophils; and/or wherein the lung injury is caused by a cytokine storm.

### Claim 25 (depends on 24)

The method of claim 24, wherein the neutrophils comprise neutrophils in the lung.

### Claim 26 (depends on 24)

The method of claim 24, wherein the cytokine storm comprises a cytokine storm in the lung.

### Claim 27 (depends on 21)

The method of claim 21, wherein the preventing and/or treating a lung injury comprises one or more features selected from the following group consisting of: (i) increasing a survival rate; (ii) increasing the blood gas PO2 and/or sO2% indicators; (iii) reducing the pulmonary inflammation; (iv) reducing the inflammatory factors in the serum; (v) improving the degree of lung tissue lesions; and (vi) decreasing the wet/dry ratio of the lung.

### Claim 28 (depends on 21)

The method of claim 21, wherein the subject is a human with an increase in the quantity of neutrophils; the increase in the quantity of neutrophils refers to a higher quantity of neutrophils A1 in the subject than a quantity of neutrophils A0 in a normal subject; and, A1/A0≥1.1.

### Claim 29 (depends on 27)

The method of claim 27, wherein the reducing the pulmonary inflammation is implemented by one or more pathways selected from the following group consisting of: (iii-1) reducing pulmonary inflammatory factors; (iii-2) reducing pulmonary white blood cells; and (iii-3) reducing pulmonary total proteins.

### Claim 30 (depends on 29)

The method of claim 29, wherein the pulmonary inflammatory factors comprise TNF-α, IL-10, IL-6, and/or IL-1β.

### Claim 31 (depends on 29)

The method of claim 29, wherein the pulmonary white blood cells comprise white blood cells, neutrophils, lymphocytes, and monocytes.

### Claim 32 (depends on 29)

The method of claim 29, wherein the reducing pulmonary inflammatory factors refers to a lower quantity of pulmonary inflammatory factors (E1) of an administrated subject than a quantity of inflammatory factors (E0) of a lung injury subject; and E0/E1≥10.

### Claim 33 (depends on 29)

The method of claim 29, wherein the reducing white blood cells refers to a lower quantity of white blood cells (F1) of the administrated subject than a quantity of white blood cells (F0) of the lung injury subject; and F0/F1≥3.

### Claim 34 (depends on 29)

The method of claim 29, wherein the reducing pulmonary total proteins refers to a lower quantity of total proteins (H1) of the administered subject than a quantity of total proteins (H0) of the lung injury subject; and H0/H1≥2.

### Claim 35 (depends on 29)

The method of claim 29, wherein the inflammatory factors in the serum comprise TNF-α, IL-10, IL-6, and/or IL-1β.

### Claim 36 (depends on 27)

The method of claim 27, wherein the reducing the inflammatory factors in the serum refers to a lower quantity of inflammatory factors (J1) in the serum of the subject than a quantity of inflammatory factors (J0) in the lung injury subject; and J0/J1≥20.

### Claim 37 (depends on 21)

The method of claim 21, further comprising another medication selected from a group consisting of: a glucocorticoid, a vitamin, and a combination thereof.

### Claim 38 (depends on 21)

The method of claim 21, wherein the annexin is in a dosage form selected from a group consisting of a powder, granules, capsules, an injection, a tincture, an oral liquid, tablets, a lozenge, a powder mist, an aerosol, and aspray.

### Claim 39 (depends on 38)

The method of claim 38, wherein the injection is an intravenous injection, an intramuscular injection, a subcutaneous formulation, or a respiratory administration formulation.

### Claim 40 (depends on 21)

The method of claim 21, wherein the administrating annexin is by oral administration, parenteral (intravenous and intramuscular) administration, and local administration.